VC funding in Europe falls short at early-stage investment hurdles
While Europe is often lauded for its robust science, late-stage investment has historically been challenging to secure. Yet speakers at …
Post
-
-
Pentagon drops WuXi AppTec from Chinese military company list
The US Department of Defence (DoD) has removed WuXi AppTec from its list of designated Chinese military companies, easing geopolitical …
-
How Kenya has become a clinical logistics hub for sub-Saharan Africa
Sub-Saharan Africa holds significant potential for clinical trials, with Kenya growing in status as a key logistics location to unlock …
-
China’s burgeoning novel medicines success presents opportunity for Europe
In recent years, China has positioned itself as a key hub for innovative medicines development, with the country having flourished …
-
Delix Therapeutics raises $100m for zalsupindole development
Delix Therapeutics has secured $100m in an oversubscribed Series C financing round to fund the development of zalsupindole (DLX001), an …
-
Charles River agrees $470m deal for Frontage assets
Charles River Laboratories International (CRL) has signed definitive agreements to acquire Frontage Holdings’ bioanalysis and drug metabolism and pharmacokinetics (DMPK) …
-
Network Bio partners with Duke University on AI disease models
US-based Network Bio has entered into a research collaboration with Duke University to develop artificial intelligence (AI) models of human …
-
Bio-Thera gains Chinese approval for spondylitis and rheumatoid arthritis drug
China's National Medical Products Administration (NMPA) has granted marketing authorisation for Bio-Thera Solutions’ BAT2506 to treat ankylosing spondylitis and rheumatoid …
-
Lonza is doubling down on US and ADC expansion with its Merck CDMO deal
Lonza’s deal to acquire almost all of Merck KGaA’s US contract development and manufacturing organisation (CDMO) network will significantly boost …
-
FDA expands J&J’s Rybrevant Faspro label with head and neck cancer approval
The US Food and Drug Administration (FDA) has authorised Johnson & Johnson’s (J&J) Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for certain …
-
MHRA champions patient voices through new policy
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has unveiled a policy to enhance the role of patients and …
-
Armada to combine with Brains Bioceutical in $750m deal
Armada Acquisition has entered a definitive business combination agreement with Brains Bioceutical that values the latter at an implied pre-money …
-
Alfasigma receives EC’s expanded approval for filgotinib to treat axSpA
Alfasigma has received expanded approval from the European Commission (EC) for Jyseleca (filgotinib) to treat adult patients living with active …
-
Cordavis to stay in CVS Health after bifurcation of $117bn empire
CVS Health will keep biosimilar subsidiary Cordavis under its umbrella, after the company announced plans to split off its pharmacy …
-
Big pharma-backed T-Therapeutics snags $133m to bring TCEs to clinic
UK-based biotech T-Therapeutics has netted $133m in a Series B financing round to bring its range of first-in-class T-cell receptor …
